Work

330: Rituximab is Feasible to Administer to Allograft Recipients with Advanced CD20+ Malignancies and does not Affect Timely Hematopoietic Engraftment

Year: 2008

Type: article

Abstract: There is limited data evaluating the feasibility of combining rituximab with conditioning chemotherapy (or chemo-radiotherapy) for patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT). Twelve patients (M = 7; F = 5), with median age of 54.5 (41–66) years, underwent allo-HCT for the following diagnoses (disease-status at transplantation) [chronic lymphocytic leukemia (CLL)= 7 (CR2 = 2; PR2 = 3; ≥PR3 = 2); mantle cell lymphoma (MCL)= 3 (CR1 = 1; ≥PR2 = 2); follicular NHL = 1 (CR3 = 1), diffuse large B-cell (DLBC) NHL = 1 (>PR3 = 1)].

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2007.12.340